162 related articles for article (PubMed ID: 20476639)
1. Bone turnover markers in patients with differentiated thyroid carcinoma after levothyroxine withdrawal.
Gao YC; Gu Q; Liu QP; Ge WL; Lu HK
Clin Lab; 2010; 56(3-4):87-93. PubMed ID: 20476639
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human TSH modulates in vivo C-telopeptides of type-1 collagen and bone alkaline phosphatase, but not osteoprotegerin production in postmenopausal women monitored for differentiated thyroid carcinoma.
Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Biondi B; Iorio S; Giustina A; Amato G; Carella C
J Bone Miner Res; 2005 Mar; 20(3):480-6. PubMed ID: 15746993
[TBL] [Abstract][Full Text] [Related]
3. Serum osteoprotegerin and soluble receptor activator of nuclear factor kappaB ligand levels in patients with a history of differentiated thyroid carcinoma: a case-controlled cohort study.
Giusti M; Cecoli F; Fazzuoli L; De Franchis V; Ceresola E; Ferone D; Mussap M; Minuto F
Metabolism; 2007 May; 56(5):699-707. PubMed ID: 17445547
[TBL] [Abstract][Full Text] [Related]
4. Receptor activator of nuclear factor kappaB ligand and osteoprotegerin in men with thyroid cancer.
Mikosch P; Igerc I; Kudlacek S; Woloszczuk W; Gallowitsch HJ; Kresnik E; Stettner H; Grimm G; Lind P; Pietschmann P
Eur J Clin Invest; 2006 Aug; 36(8):566-73. PubMed ID: 16893379
[TBL] [Abstract][Full Text] [Related]
5. Bone mineral density changes and bone turnover in thyroid carcinoma patients treated with supraphysiologic doses of thyroxine.
Karner I; Hrgović Z; Sijanović S; Buković D; Klobucar A; Usadel KH; Fassbender WJ
Eur J Med Res; 2005 Nov; 10(11):480-8. PubMed ID: 16354602
[TBL] [Abstract][Full Text] [Related]
6. Skeletal integrity in men chronically treated with suppressive doses of L-thyroxine.
Marcocci C; Golia F; Vignali E; Pinchera A
J Bone Miner Res; 1997 Jan; 12(1):72-7. PubMed ID: 9240728
[TBL] [Abstract][Full Text] [Related]
7. Circulating adiponectin concentrations were related to free thyroxine levels in thyroid cancer patients after thyroid hormone withdrawal.
Lin SY; Huang SC; Sheu WH
Metabolism; 2010 Feb; 59(2):195-9. PubMed ID: 19765779
[TBL] [Abstract][Full Text] [Related]
8. Biologic blood markers reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Földes J; Tarján G; Bános C; Németh J; Varga F; Büki B
Acta Med Hung; 1991; 48(1-2):33-43. PubMed ID: 1813856
[TBL] [Abstract][Full Text] [Related]
9. Replacement therapy with levothyroxine plus triiodothyronine (bioavailable molar ratio 14 : 1) is not superior to thyroxine alone to improve well-being and cognitive performance in hypothyroidism.
Siegmund W; Spieker K; Weike AI; Giessmann T; Modess C; Dabers T; Kirsch G; Sänger E; Engel G; Hamm AO; Nauck M; Meng W
Clin Endocrinol (Oxf); 2004 Jun; 60(6):750-7. PubMed ID: 15163340
[TBL] [Abstract][Full Text] [Related]
10. Bone metabolism in patients with differentiated thyroid carcinoma receiving suppressive levothyroxine treatment.
Mikosch P; Obermayer-Pietsch B; Jost R; Jauk B; Gallowitsch HJ; Kresnik E; Leb G; Lind P
Thyroid; 2003 Apr; 13(4):347-56. PubMed ID: 12804103
[TBL] [Abstract][Full Text] [Related]
11. Biologic markers in blood reflecting thyroid hormone effect at peripheral tissue level in patients receiving levothyroxine replacement for hypothyroidism.
Földes J; Tarján G; Bános C; Németh J; Varga F; Büki B
Exp Clin Endocrinol; 1992; 99(3):129-33. PubMed ID: 1526260
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of osteocalcin in bone metastatic differentiated thyroid carcinoma.
Gao Y; Lu H; Luo Q; Wu X; Sheng S
Clin Biochem; 2010 Feb; 43(3):291-5. PubMed ID: 19732762
[TBL] [Abstract][Full Text] [Related]
13. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
14. Thyrotropin versus thyroid hormone in regulating bone density and turnover in premenopausal women.
Baqi L; Payer J; Killinger Z; Hruzikova P; Cierny D; Susienkova K; Langer P
Endocr Regul; 2010 Apr; 44(2):57-63. PubMed ID: 20429634
[TBL] [Abstract][Full Text] [Related]
15. Determinants of bone turnover markers in healthy premenopausal women.
Adami S; Bianchi G; Brandi ML; Giannini S; Ortolani S; DiMunno O; Frediani B; Rossini M;
Calcif Tissue Int; 2008 May; 82(5):341-7. PubMed ID: 18470550
[TBL] [Abstract][Full Text] [Related]
16. Body mass index (BMI) and parameters of bone formation and resorption in postmenopausal women.
Papakitsou EF; Margioris AN; Dretakis KE; Trovas G; Zoras U; Lyritis G; Dretakis EK; Stergiopoulos K
Maturitas; 2004 Mar; 47(3):185-93. PubMed ID: 15036488
[TBL] [Abstract][Full Text] [Related]
17. A slightly suppressive dose of L-thyroxine does not affect bone turnover and bone mineral density in pre- and postmenopausal women with nontoxic goitre.
De Rosa G; Testa A; Maussier ML; Callà C; Astazi P; Albanese C
Horm Metab Res; 1995 Nov; 27(11):503-7. PubMed ID: 8770627
[TBL] [Abstract][Full Text] [Related]
18. Free thyroxine, free triiodothyronine, and thyrotropin concentrations in hypothyroid and thyroid carcinoma patients receiving thyroxine therapy.
Liewendahl K; Helenius T; Lamberg BA; Mähönen H; Wägar G
Acta Endocrinol (Copenh); 1987 Nov; 116(3):418-24. PubMed ID: 3687325
[TBL] [Abstract][Full Text] [Related]
19. Circulating resistin levels are lower in hypothyroid women but independent from thyroid hormones concentrations.
Owecki M; El Ali Z; Waśko R; Nikisch E; Sowiński J
Neuro Endocrinol Lett; 2008 Feb; 29(1):131-6. PubMed ID: 18283268
[TBL] [Abstract][Full Text] [Related]
20. [Hormone therapy as postoperative care in patients with differentiated thyroid cancer].
Kurihara H; Kuwahara T; Nakano Y
Nihon Geka Gakkai Zasshi; 1987 Oct; 88(10):1415-22. PubMed ID: 3696136
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
